ReviewMagyar onkologia2026
[Lymphatic mapping and sentinel node biopsy in penile cancer: from the cradle of the technique to current perspectives].
Review in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymph node status is the most important prognostic factor in penile squamous cell carcinoma, yet radical inguinal lymph node dissection (ILND) carries substantial morbidity. Sentinel lymph node biopsy was pioneered in penile cancer and subsequently evolved to a concept of dynamic sentinel node biopsy (DSNB), a multidisciplinary staging procedure integrating radiotracer injection, lymphoscintigraphy, intraoperative localization, and pathological ultrastaging with high dianostic efficiency. Over time, gradual improvements including preoperative ultrasonography with fine-needle aspiration cytology (FNAC), SPECT/CT, more refined pathological assessment, and hybrid tracers have reduced false-negative rates improving reliability in experienced centers. Current EAU-ASCO guidance supports DSNB as the preferred surgical strategy to stage patients with intermediate- and high-risk clinically node-negative (cN0) penile cancer. This review summarizes the historical development of penile sentinel node surgery, the current DSNB evidence, the role of modern imaging and hybrid tracers as well as persistent limitations of the approach such as non-visualization, false-negative rate, and other important areas in which further standardization and innovation are needed.
Indexed as
Identifiers
42730997PMC13577720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.